Factors determining the remission of microprolactinomas after dopamine agonist withdrawal
M. S. B. Huda(Guy's and St Thomas' NHS Foundation Trust), Jake Powrie(Guy's and St Thomas' NHS Foundation Trust), Ming Ming Teh, N. Athauda(Guy's and St Thomas' NHS Foundation Trust), Paul Carroll(Guy's and St Thomas' NHS Foundation Trust)
Cited by 67
Related Papers
Blood and Islet Phenotypes Indicate Immunological Heterogeneity in Type 1 Diabetes
|Diabetes|2014|244
Dietary isothiocyanates, glutathione S-transferase -M1, -T1 polymorphisms and lung cancer risk among Chinese women in Singapore.
|PubMed|2001|219
Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetes
|Science Translational Medicine|2017|215
Peripheral and Islet Interleukin-17 Pathway Activation Characterizes Human Autoimmune Diabetes and Promotes Cytokine-Mediated β-Cell Death
|Diabetes|2011|213
Self‐monitoring in Type 2 diabetes mellitus: a meta‐analysis
|Diabetic Medicine|2000|177